PART B-FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS"

Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. VENABLE LLP P.O. Box 34385 Washington, DC 20043-9998 I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelop addressed to the Mail Stop ISSUE FEE address above, or being facsimil transmitted to the USPTO (571) 273-2885, on the date indicated below. (Depositor's name (Signature)	or maintenance fee notifications.						
Thereby certify that this Fee(s) Transmittal is being deposited with the United Safe Postal Service with sufficient posts for first class mail in an envelop addressed to the Mail Stop ISSUE_FEE address above, or being fiscaling in an envelop addressed to the Mail Stop ISSUE_FEE address above, or being fiscaling in an envelop addressed to the Mail Stop ISSUE_FEE address above, or being fiscaling intermediate to the USPTO (571) 273-2858, on the date indicated below. Composition Comp	VENABLE LLP	1 1					
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFRMATION NO. 10/90/900 02/20/2007 Andrea Buchacher 37998-237524 4370 TITLE OF INVENTION: A METHOD OF PROVIDING A PURIFIED, VIRUS SAFE ANTIBODY PREPARATION APPLN TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE Non-Provisional no \$1,510.00 \$300.00 \$1,810.00 05/27/2009 EXAMINER ART UNIT CLASS-SUBCLASS D. A. Saunders 1644 1. Change of correspondence address or indication of "Fee Address" indication in season and the patient of the patient				I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.			
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/590,900 02/20/2007 Andrea Buchacher 37998-237524 4370 TITLE OF INVENTION: A METHOD OF PROVIDING A PURIFIED, VIRUS SAFE ANTIBODY PREPARATION APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE Non-Provisional no \$1,510.00 \$300.00 \$1,810.00 05/27/2009 EXAMINER ART UNIT CLASS-SUBCLASS D. A. Saunders 1644 1. Change of correspondence address or indication of "Fee Address" indication (or "Fee Address" indication form PTO/50/847; Rev 30-20 or more recent) attached. The Address of the Address from PTO/SBL2 attached. The Addre						(Depositor's name)	
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/99,900 02/20/2007 Andrea Buchacher 37998-237524 4370 TITLE OF INVENTION: A METHOD OF PROVIDING A PURIFIED, VIRUS SAFE ANTIBODY PREPARATION A METHOD OF PROVIDING A PURIFIED, VIRUS SAFE ANTIBODY PREPARATION A METHOD OF PROVIDING A PURIFIED, VIRUS SAFE ANTIBODY PREPARATION APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE Non-Provisional no \$1,510.00 \$300.00 \$1,810.00 05/27/2009 EXAMINER ART UNIT CLASS-SUBCLASS D. A. Saunders 16/44 I. Change of correspondence address (or Change of Correspondence Address from PIO/SBI 22) attached. The Correspondence Address from PIO/SBI 22) attached. The Correspondence Address from PIO/SBI 22) attached. The Correspondence Address from Safe indication from PIO/SBI 22) attached. Use of a Customer Number is required. The Address' 3/3 CFR 1.363. Change of correspondence address (or Change of Correspondence Address from PIO/SBI 22) attached. The Correspondence Address from Safe indication from PIO/SBI 23, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 23, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 247, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 247, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 247, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 247, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 247, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 247, Rev 03-02 or more recent) attached. The Correspondence Address from Safe indication from PIO/SBI 247, Rev 03-02 or more recent) attached page or the patent of Page 25 or Safe 127 (B) Respondence of Page 25 or Safe 127 (B) Respondence or Page 25 or Safe 127 (B) Re						(Signature)	
TITLE OF INVENTION: A METHOD OF PROVIDING A PURIFIED, VIRUS SAFE ANTIBODY PREPARATION APPLN: TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE Non-Provisional no \$1,510.00 \$300.00 \$1,810.00 05/27/2009 EXAMINER ART UNIT CLASS-SUBCLASS D. A. Saunders 1644 I. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363) Change of correspondence Address form PTO/SB/122) attached. "Fee Address indication (or "Fee Address Indication form PTO/SB/122) attached. "Fee Address indication (or "Fee Address Indication form PTO/SB/122) attached. "Stee Address indication (or "Fee Address Indication form PTO/SB/122) attached. "Stee Address Indication (or "Fee Address Indication form PTO/SB/122) attached. "Stee Address Indication (or "Fee Address Indication form PTO/SB/122) attached. "Stee Address Indication (or "Fee Address Indication form PTO/SB/122) attached. "Stee Address Indication (or "Fee Address Indication form PTO/SB/122) attached. "Stee Address Indication (or "Fee Address Indication form PTO/SB/122) attached. "Stee Address Indication (or "Fee Address Indication form PTO/SB/122) attached. "A SSIGNEE DATA TO BE PRINTED ON THE PATENT (print or Type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (a) NAME OF ASSIGNEE OCTAPHARMA AG LACHEN, SWITZERLAND Plesse check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Publication Fee (No small entity discount permitted) Advance Order # of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 2-2-0261 Deposit Account Number 2-2-0261 Authorized Signature Date S122/03						(Date)	
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE Non-Provisional no \$1,510.00 \$300.00 \$1,810.00 05/27/2009 EXAMINER ART UNIT CLASS-SUBCLASS D. A. Saunders 1644 1. Change of correspondence address or indication of "Fee Address" indication (or "Fee Address" indication from PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE OCTAPHARMA AG LACHEN, SWITZERLAND Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity				OR			
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DUE Non-Provisional no \$1,510.00 \$300.00 \$1,810.00 05/27/2009 EXAMINER ART UNIT CLASS-SUBCLASS D. A. Saunders 1644 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address or indication of "Fee Address" indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) OCAPHARMA AG LACHEN, SWITZERLAND Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Publication Fee (No small entity discount permitted) Advance Order # of Copies A Payment of Fee(s): A Phesicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27 b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27 b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27 b. Authorized Signature Date SIZZ/09	10/590,900 02/20/2007	2007 Andrea Buchacher			37998-237524 4370		
Non-Provisional No \$1,510.00 \$300.00 \$1,810.00 05/27/2009	TITLE OF INVENTION: A METHOD OF	PROVIDING A PURIFIED	, VIRUS SAI	FE ANTIBOD	Y PREPARATION		
EXAMINER D. A. Saunders 1644 1. Change of correspondence address or indication of "Fee Address" indication of "Fee Address" indication of "Fee Address" indication (or "Fee Address" indication of "Fee Address" indication (or "Fee Address" indication of "Fee Address" indication (or "Fee Address" indicati	APPLN. TYPE SMALL ENTITY	ISSUE FEE	PUBLICA	TION FEE	TOTAL FEE(S) DUE	DATE DUE	
D. A. Saunders 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address from PTO/SB1/22) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB1/22) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB1/22) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB1/27, Rev 03-02 or more recent) attached. "See Address" indication (or "Fee Address" Indication form PTO/SB1/27, Rev 03-02 or more recent) attached. "Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) OCTAPHARMA AG LACHEN, SWITZERLAND Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Publication Fee (No small entity discount permitted) Advance Order # of Copies Advance Order # of Copies Advance Order # of Copies A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if equired) will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assign	Non-Provisional no	\$1,510.00	\$300.00		\$1,810.00	05/27/2009	
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence address (or Change of Correspondence Address form PTO/SBA/22) attached. "Fee Address" indication (or "Fee Address" indication form PTO/SBA/22) attached. "Is en Address indication (or "Fee Address" indication form PTO/SBA/37, Rev 0.3-02 or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE OCTAPHARMA AG LACHEN, SWITZERLAND Please check the appropriate assignee category or categories (will not be printed on the patent): I Issue Fee Advance Order # of Copies A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. Advance Order # of Copies A check in the amount of the fee(s) is enclosed. The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 S. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27 (g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. OTTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered attomey or agent, or the assignee or other party interest as shown by the records of the United Stages Yarga and Trademark (Pffee)	EXAMINER	ART UNIT	JNIT CLASS-SUB				
Address" (37 CFR 1,363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/12) or more recent) attached. Use of a Customer Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE OCTAPHARMA AG LACHEN, SWITZERLAND Please check the appropriate assignee category or categories (will not be printed on the patent): I saue Fee A check in the amount of the fee(s) is enclosed. Ye publication Fee (No small entity discount permitted) Advance Order -# of Copies A check in the amount of the fee(s) is enclosed. Ye payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. b Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27. Authorized Signature Date \$\frac{1 \text{Venable LLP}}{Ann S. Hobbs} Ann S. Hobbs Ann S. Hobb							
International Processor States (1987) (1986) (1987)	Address" (37 CFR i.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication a registered attorney or agent) and the names of Up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of Up to 3 registered patent attorneys or agents OR, alternatively, attorneys or agents OR, altern						
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) OCTAPHARMA AG LACHEN, SWITZERLAND Please check the appropriate assignee category or categories (will not be printed on the patent): At The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. A divance Order # of Copies The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) a Applicant claims SMALL ENTITY status. See 37 CFR 1.27. The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Parent and Trademark Office) Authorized Signature Date STATE OR COUNTRY) LACHEN, SWITZERLAND LACHEN, SWITZERLAND LACHEN, SWITZERLAND LACHEN, SWITZERLAND A check in the amount of the fee(s) is enclosed. A check in the amount of the fee(s) is enclosed. A check in the amount of the fee(s) is enclosed. A check in the amount of the fee(s) is enclosed. A check in the amount of the fee(s) is enclosed. B A check in the amount of the fee(s) is enclosed. A check in the amount of the fee(s) is enclosed. B A check in the amount of the fee(s) is enclosed. B A check in the amount of the fee(s) is enclosed. B A check in the amount of the fee(s) is enclosed. B A check in the amount of the fee(s) is enclosed. B A check in the amount of the fee(s) is enclosed. B A check in the	101111 F 1 O/3B/47, Rev 03-02 of more recent attached.				ents. If no 3 Matthew	E. Kelley	
for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) OCTAPHARMA AG LACHEN, SWITZERLAND Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Patent and Trademark Office) Authorized Signature Date 5/22/09							
Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. X Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) A Applicant claims SMALL ENTITY status. See 37 CFR 1.27. The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United Stages Patent and Trademark Office. Date 5/22/09	for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.						
Please check the appropriate assignee category or categories (will not be printed on the patent): Individual X Corporation or other private group entity Government 4a. The following fee(s) are enclosed: X Issue Fee A check in the amount of the fee(s) is enclosed. Payment by credit card. Form PTO-2038 is attached. Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Patent and Trademark Office. Date 5/22/09							
X Issue Fee							
X Issue Fee	4a. The following fee(s) are enclosed:	4b. 1	Payment of F	ee(s):			
Advance Order -# of Copies X The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date 5/22/09	x Issue Fee	A che	ck in the amo	ount of the fee(s	s) is enclosed.		
Deposit Account Number 22-0261 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date 5/22/09	x Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached.						
a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date 5/22/09							
The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date 5/22/09	5. Change in Entity Status (from status indicate	d above)	_				
NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date 5/22/09		<u> </u>					
<u> </u>	NOTE: The Issue Fee and Publication Fee (if require	 d) will not be accepted from a 	inyone other t	e-apply any prev han the applicar	viously paid issue fee to the ap nt; a registered attorney or age	plication identified above. nt; or the assignee or other party ir	
Typed or printed name Matthew E. Kelley Registration No 55,887	Authorized Signature	In E. Kills	>		Date <u>5/22</u>	109	
	Typed or printed name	Matthew E. Kelley	<u> </u>		Registration No.	55,887	